Search
Castle Biosciences Inc
CSTLAdd to Watchlist
34.710USD
-0.170-0.49%
Market hours 09/24, 15:19（ET）
1.05BMarket Cap
LossP/E TTM
About Castle Biosciences Inc Company
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
Castle Biosciences Inc Profile
Ticker SymbolCSTL
Company nameCastle Biosciences Inc
IPO dateJul 25, 2019
CEOMaetzold (Derek J)
Number of employees761
Security typeOrdinary Share
Fiscal year-endJul 25
Address505 S Friendswood Drive
CityFRIENDSWOOD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code77546
Phone18667889007
Websitehttps://castlebiosciences.com/
Ticker SymbolCSTL
IPO dateJul 25, 2019
CEOMaetzold (Derek J)
Company Executives of Castle Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Derek J. Maetzold
Mr. Derek J. Maetzold
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
279.21K
--
Mr. Derek J. Maetzold
Mr. Derek J. Maetzold
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
279.21K
--
Mr. Derek J. Maetzold
Mr. Derek J. Maetzold
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
279.21K
--
Ms. Kristen M. Oelschlager
Ms. Kristen M. Oelschlager
Chief Operating Officer
Chief Operating Officer
110.54K
--
Ms. Kristen M. Oelschlager
Ms. Kristen M. Oelschlager
Chief Operating Officer
Chief Operating Officer
110.54K
--
Ms. Kristen M. Oelschlager
Ms. Kristen M. Oelschlager
Chief Operating Officer
Chief Operating Officer
110.54K
--
Mr. Tobin W. (Toby) Juvenal
Mr. Tobin W. (Toby) Juvenal
Chief Commercial Officer
Chief Commercial Officer
59.88K
-11.02%
Mr. Tobin W. (Toby) Juvenal
Mr. Tobin W. (Toby) Juvenal
Chief Commercial Officer
Chief Commercial Officer
59.88K
-11.02%
Mr. Tobin W. (Toby) Juvenal
Mr. Tobin W. (Toby) Juvenal
Chief Commercial Officer
Chief Commercial Officer
59.88K
-11.02%
Ms. Ellen Goldberg
Ms. Ellen Goldberg
Independent Director
Independent Director
40.92K
+33.40%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Derek J. Maetzold
Mr. Derek J. Maetzold
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
279.21K
--
Mr. Derek J. Maetzold
Mr. Derek J. Maetzold
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
279.21K
--
Mr. Derek J. Maetzold
Mr. Derek J. Maetzold
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
279.21K
--
Ms. Kristen M. Oelschlager
Ms. Kristen M. Oelschlager
Chief Operating Officer
Chief Operating Officer
110.54K
--
Ms. Kristen M. Oelschlager
Ms. Kristen M. Oelschlager
Chief Operating Officer
Chief Operating Officer
110.54K
--
Ms. Kristen M. Oelschlager
Ms. Kristen M. Oelschlager
Chief Operating Officer
Chief Operating Officer
110.54K
--
FAQs
Who are the top five shareholders of Castle Biosciences Inc?
The top five shareholders of Castle Biosciences Inc are: Mr. Derek J. Maetzold
How many institutions hold shares of Castle Biosciences Inc (CSTL)?
As of 2026Q1, 413 institutions hold shares of Castle Biosciences Inc, with a combined market value of approximately 27.62M, accounting for 91.06% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1802863.00.